Biomarkers are needed to accurately predict short-term breast cancer risk, so that 1) women who are most likely to benefit from preventive therapy can be identified, and 2) response to chemoprevention can be accurately assessed. This proposal aims to characterize a signal-transduction pathway that we hypothesize plays an important role in targeting the elimination of acutely damaged mammary epithelial cells. In preclinical models, we observe that 1) the retinoic acid receptor-beta 2 (RARbeta2) and the CREB-binding protein, CBP, regulate proliferation and promote apoptosis in acutely damaged mammary epithelial cells, 2) RARbeta2 regulates the expression of CBP in a positive feedback loop, and 3) suppression of RARbeta2 or CBP inhibits apoptosis. Based on these observations we will test the hypothesis that 1) RARbeta2 and CBP promote apoptosis in acutely damaged HMECs through IRF-1-induction and 2) RARbeta2 P2 methylation predicts loss of CBP expression in mammary epithelial cells obtained from high-risk women.
Specific Aim I will test whether RARbeta2 and CBP promote apoptosis in acutely damaged HMECs through recruitment to the IRF-1 promoter and indution of IRF-1.
Specific Aim II will test whether the presence of RARbeta2 P2 promoter methylation predicts loss of CBP expression in mammary epithelial cell strains obtained from women at high-risk from breast cancer.
Specific Aim III will use a research technique called Random Periareolar Fine Needle Aspirate (RPFNA) to test whether methylation inactivation of RARbeta2 in high-risk women promotes 1) loss of RARbeta2 and CBP expression and 2) predicts short-term cytological progression. The correlation between RARbeta2 P2 methylation and CBP expression in RPFNA will be tested by MS-PCR and quantitative RT-PCR in microdissected epithelial cell clusters. Cytological progression will be tested in high-risk women in our chemoprevention cohort. Relevance to public health: Information obtained in this proposal can be immediately used to 1) improve our ability to predict short-term breast cancer-risk and 2) develop makers to test whether women who are at high-risk for breast cancer are responding to prevention agents.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA114068-05
Application #
7893701
Study Section
Cancer Biomarkers Study Section (CBSS)
Program Officer
Wang, Wendy
Project Start
2006-08-01
Project End
2013-07-31
Budget Start
2010-08-01
Budget End
2013-07-31
Support Year
5
Fiscal Year
2010
Total Cost
$261,331
Indirect Cost
Name
Duke University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Ibarra-Drendall, Catherine; Troch, Michelle M; Barry, William T et al. (2012) Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways. Breast Cancer Res Treat 132:487-98
Seewaldt, Victoria L (2012) Cancer: Destiny from density. Nature 490:490-1
D'Amato, Nicholas C; Ostrander, Julie H; Bowie, Michelle L et al. (2012) Evidence for phenotypic plasticity in aggressive triple-negative breast cancer: human biology is recapitulated by a novel model system. PLoS One 7:e45684
Henderson, Brian E; Lee, Norman H; Seewaldt, Victoria et al. (2012) The influence of race and ethnicity on the biology of cancer. Nat Rev Cancer 12:648-53
Pilie, Patrick G; Ibarra-Drendall, Catherine; Troch, Michelle M et al. (2011) Protein microarray analysis of mammary epithelial cells from obese and nonobese women at high risk for breast cancer: feasibility data. Cancer Epidemiol Biomarkers Prev 20:476-82
Vasilatos, Shauna N; Broadwater, Gloria; Barry, William T et al. (2009) CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis. Cancer Epidemiol Biomarkers Prev 18:901-14
Ibarra-Drendall, Catherine; Wilke, Lee G; Zalles, Carola et al. (2009) Reproducibility of random periareolar fine needle aspiration in a multi-institutional Cancer and Leukemia Group B (CALGB) cross-sectional study. Cancer Epidemiol Biomarkers Prev 18:1379-85
Baker Jr, Joseph C; Ostrander, Julie H; Lem, Siya et al. (2008) ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention. Cancer Epidemiol Biomarkers Prev 17:1884-90
Bowie, M L; Troch, M M; Delrow, J et al. (2007) Interferon regulatory factor-1 regulates reconstituted extracellular matrix (rECM)-mediated apoptosis in human mammary epithelial cells. Oncogene 26:2017-26
Seewaldt, Victoria L; Goldenberg, Vanessa; Jones, Lee W et al. (2007) Overweight and obese perimenopausal and postmenopausal women exhibit increased abnormal mammary epithelial cytology. Cancer Epidemiol Biomarkers Prev 16:613-6